Adalimumab
"Adalimumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.
Descriptor ID |
D000068879
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.250 D12.776.124.790.651.114.224.060.250 D12.776.377.715.548.114.224.200.250
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adalimumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Adalimumab [D12.776.124.486.485.114.224.060.250]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Adalimumab [D12.776.124.790.651.114.224.060.250]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Adalimumab [D12.776.377.715.548.114.224.200.250]
Below are MeSH descriptors whose meaning is more specific than "Adalimumab".
This graph shows the total number of publications written about "Adalimumab" by people in this website by year, and whether "Adalimumab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 | 2003 | 0 | 3 | 3 | 2004 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2008 | 0 | 2 | 2 | 2009 | 0 | 3 | 3 | 2011 | 0 | 2 | 2 | 2014 | 1 | 2 | 3 | 2015 | 1 | 1 | 2 | 2016 | 0 | 2 | 2 | 2017 | 2 | 0 | 2 | 2019 | 1 | 0 | 1 | 2020 | 2 | 3 | 5 | 2021 | 0 | 2 | 2 | 2022 | 0 | 3 | 3 | 2023 | 0 | 2 | 2 | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adalimumab" by people in Profiles.
-
Thomas T, Friedrich M, Rich-Griffin C, Pohin M, Agarwal D, Pakpoor J, Lee C, Tandon R, Rendek A, Aschenbrenner D, Jainarayanan A, Voda A, Siu JHY, Sanches-Peres R, Nee E, Sathananthan D, Kotliar D, Todd P, Kiourlappou M, Gartner L, Ilott N, Issa F, Hester J, Turner J, Nayar S, Mackerodt J, Zhang F, Jonsson A, Brenner M, Raychaudhuri S, Kulicke R, Ramsdell D, Stransky N, Pagliarini R, Bielecki P, Spies N, Marsden B, Taylor S, Wagner A, Klenerman P, Walsh A, Coles M, Jostins-Dean L, Powrie FM, Filer A, Travis S, Uhlig HH, Dendrou CA, Buckley CD. A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease. Nat Immunol. 2024 Nov; 25(11):2152-2165.
-
Coleman MS, Mulligan KM, O'Connell KA, Ahmad A, Kim L, da Silva A, Newton J, Dellavalle RP. Review of therapeutic trends in clinical trials for hidradenitis suppurativa: the?rise of biologics and demographic under-representation. Clin Exp Dermatol. 2024 Jan 25; 49(2):172-173.
-
White S, Morrow R, Pan I, de Zoeten EF. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr. 2023 06; 76(6):701-703.
-
Gibbons JB, Laber M, Bennett CL. Humira: the first $20 billion drug. Am J Manag Care. 2023 02; 29(2):78-80.
-
Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022 10 14; 10:CD013818.
-
Kerur B, Fiedler K, Stahl M, Hyams J, Stephens M, Lu Y, Pfefferkorn M, Alkhouri R, Strople J, Kelsen J, Siebold L, Goyal A, Rosh JR, LeLeiko N, Van Limbergen J, Guerrerio AL, Maltz RM, Karam L, Crowley E, Griffiths AM, Heyman MB, Deneau M, Benkov K, Noe J, Moulton D, Pappa H, Galanko J, Snapper S, Muise AM, Kappelman MD, Benchimol EI. Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):64-69.
-
Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022 06; 64:102234.
-
Haydek JP, Scott FI. Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence. Aliment Pharmacol Ther. 2021 09; 54(6):846-847.
-
Sobolewska B, Baglivo E, Edwards AO, Kramer M, Miserocchi E, Palestine AG, Schwab IR, Zamir E, Doycheva D, Zierhut M. Drug-induced Sarcoid Uveitis with Biologics. Ocul Immunol Inflamm. 2022 May 19; 30(4):907-914.
-
Hoshitsuki K, Rathod S, Ramsey MJ, Zhu L, Moreland LW, Fernandez CA. Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. J Pharmacol Exp Ther. 2020 12; 375(3):488-497.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|